Benzinga
-
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …
-
6 Companies That Could Fix Domestic Battery Supply Problem Using Little To No Emissions In The Mining of Essential Minerals
Previously Published to NewsBreak SUMMARY: When we talk about the essential elements of an electric vehicle (EV) battery, graphite, more times than not, seems to be left out of the conversation. Recently, that all changed after news got out that there may be a global graphite deficit starting in 2022. This comes at a time when industry movers and shakers are preparing for a massive EV boom, and demand from the battery sector is expected to rise by 30% annually until 2030. And actually, the demand for domestic battery products may all be in vain unless something is done, otherwise, to save it. While making the point that China controls 84% of…
-
Digital Transformation Of Emerging Markets Could Mean Continued Opportunity For Newly NASDAQ Listed Japanese Company
Previously published on Benzinga HeartCore Enterprises Inc. (NASDAQ: HTCR) is a software-as-a-service (SaaS) solutions provider and leading development company in the enterprise business sector. In February, the company was uplisted to the Nasdaq Stock Exchange and rang the opening bell. Last June, Founder and CEO Sumitaka Kanno was honored with the Top 100 Tech Innovators & Influencers Award at InterCon Las Vegas for his significant and tangible contributions to the world of technology. HeartCore already held the largest market share in Japan for six straight years. It All Started With A Vision Founded in 2009, HeartCore (formerly XyXon Inc.) entered the market with its cornerstone HeartCore CMS rich content management…
-
MedTech Company BioSig Technologies Deploys Disruptive Technology To Improve Arrhythmia Care
This article was previously published to Benzinga. Arrhythmia is a heart condition that causes it to beat either too fast, or irregularly. It’s triggered by abnormal electrical activity and affects the heart’s rhythm, leading it to beat out of sync with the rest of the body. Not every patient experiences arrhythmia in the same way, so it’s sometimes necessary for doctors to provide each patient with a personalized approach to treatment and recovery. Lifestyle choices and comorbidities, medication, stress and environmental factors can cause the heart to beat out of sync. The world is experiencing an uptick in arrhythmia cases linked to the after effects of COVID-19. Atrial fibrillation (AFib) is the…
-
Is It Time To Have A Talk About Poor Ventilation Post COVID-19?
This article was previously published on Benzinga. The average person takes more than 20,000 breaths per day. In fact, by the time they’re 50 years of age, they may have taken somewhere around 400 million breaths in their lifetime. Breathing is essential, and indoor air quality (IAQ) really does matter. Reportedly, the average commercial office building produces more than 39% of the world’s carbon emissions. That energy consumption may impair more than just the climate. Society spends most of its time indoors. And for the modern world, much of this time may be spent living with poor IAQ. IAQ — A Serious Concern? “Good IAQ is directly linked to higher productivity…
